This review highlights the history of the development of treatments for choroidal neovascularization (wct AMD). It examines how drug therapies have evolved for the management of age-related macular degeneration (AMD) and the value of randomised clinical trials in determining efficacy. Finally it examines the emerging practice of utilising bevacizumab for the treatment of choroidal neovascularization despite the lack of any phase III clinical trial data.
机构:
Southampton Gen Hosp, Div Human Genet, Southampton SO16 6YD, Hants, EnglandSouthampton Gen Hosp, Div Human Genet, Southampton SO16 6YD, Hants, England
Canning, C.
Lotery, A.
论文数: 0引用数: 0
h-index: 0
机构:
Southampton Gen Hosp, Div Human Genet, Southampton SO16 6YD, Hants, EnglandSouthampton Gen Hosp, Div Human Genet, Southampton SO16 6YD, Hants, England
机构:University Hospital Southampton,Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, South Lab and Path Block, Mailpoint 806, Level D
Andrew J. Lotery
Michael A. Burdon
论文数: 0引用数: 0
h-index: 0
机构:University Hospital Southampton,Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, South Lab and Path Block, Mailpoint 806, Level D